{"title":"使用阿加西酶 alfa 成功治疗了一名在使用阿加西酶 beta 后出现过敏性休克的法布里病患者:病例报告。","authors":"Mehmet Erdem Cakmak","doi":"10.14744/nci.2022.45656","DOIUrl":null,"url":null,"abstract":"<p><p>Fabry disease is a rare genetic disease caused by a deficiency of α-galactosidase A gene (α-Gal A). Two intravenous enzymes administered every two weeks, agalsidase alfa and beta can slow disease progression and increase survival if administered early, before organ damage occurs. In this case report, we present a patient with a history of anaphylaxis to agalsidase beta who was successfully treated with agalsidase alfa.</p>","PeriodicalId":46465,"journal":{"name":"Archaeology in Oceania","volume":"29 1","pages":"88-90"},"PeriodicalIF":1.1000,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10861426/pdf/","citationCount":"0","resultStr":"{\"title\":\"Successful treatment using agalsidase alfa of a patient with Fabry disease who had anaphylaxis after agalsidase beta: A case report.\",\"authors\":\"Mehmet Erdem Cakmak\",\"doi\":\"10.14744/nci.2022.45656\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Fabry disease is a rare genetic disease caused by a deficiency of α-galactosidase A gene (α-Gal A). Two intravenous enzymes administered every two weeks, agalsidase alfa and beta can slow disease progression and increase survival if administered early, before organ damage occurs. In this case report, we present a patient with a history of anaphylaxis to agalsidase beta who was successfully treated with agalsidase alfa.</p>\",\"PeriodicalId\":46465,\"journal\":{\"name\":\"Archaeology in Oceania\",\"volume\":\"29 1\",\"pages\":\"88-90\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-01-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10861426/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archaeology in Oceania\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14744/nci.2022.45656\",\"RegionNum\":3,\"RegionCategory\":\"历史学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ANTHROPOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archaeology in Oceania","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/nci.2022.45656","RegionNum":3,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ANTHROPOLOGY","Score":null,"Total":0}
Successful treatment using agalsidase alfa of a patient with Fabry disease who had anaphylaxis after agalsidase beta: A case report.
Fabry disease is a rare genetic disease caused by a deficiency of α-galactosidase A gene (α-Gal A). Two intravenous enzymes administered every two weeks, agalsidase alfa and beta can slow disease progression and increase survival if administered early, before organ damage occurs. In this case report, we present a patient with a history of anaphylaxis to agalsidase beta who was successfully treated with agalsidase alfa.
期刊介绍:
Archaeology in Oceania is published online and in print versions three times a year: April, July, October. It accepts articles and research reports in prehistoric and historical archaeology, modern material culture and human biology of ancient and modern human populations. Its primary geographic focus is Australia, the islands of the Pacific Ocean and lands of the western Pacific rim. All articles and research reports accepted as being within the remit of the journal and of appropriate standard will be reviewed by two scholars; authors will be informed of these comments though not necessarily of the reviewer’s names.